Crystal structure of S-adenosyl-L-homocysteine hydrolase from the human malaria parasite Plasmodium falciparum

被引:66
作者
Tanaka, N
Nakanishi, M
Kusakabe, Y
Shiraiwa, K
Yabe, S
Ito, Y
Kitade, Y
Nakamura, KT
机构
[1] Showa Univ, Sch Pharmaceut Sci, Shinjuku Ku, Tokyo 1428555, Japan
[2] Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan
关键词
crystal structure; drug design; inhibitor; malaria;
D O I
10.1016/j.jmb.2004.08.104
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The human malaria parasite Plasmodium falciparum is responsible for the death of more than a million people each year. The emergence of strains of malarial parasite resistant to conventional drug therapy has stimulated searches for antimalarials with novel modes of action. S-Adenosyl-L-homocysteine hydrolase (SAHH) is a regulator of biological methylations. Inhibitors of SAHH affect the methylation status of nucleic acids, proteins, and small molecules. P. falciparum SAHH (PfSAHH) inhibitors are expected to provide a new type of chemotherapeutic agent against malaria. Despite the pressing need to develop selective PfSAHH inhibitors as therapeutic drugs, only the mammalian SAHH structures are currently available. Here, we report the crystal structure of PfSAHH complexed with the reaction product adenosine (Ado). Knowledge of the structure of the Ado complex in combination with a structural comparison with Homo sapiens SAHH (HsSAHH) revealed that a single substitution between the PfSAHH (Cys59) and HsSAHH (Thr60) accounts for the differential interactions with nucleoside inhibitors. To examine roles of the Cys59 in the interactions with nucleoside inhibitors, a mutant PfSAHH was prepared. A replacement of Cys59 by Thr results in mutant PfSAHH, which shows HsSAHH-like nucleoside inhibitor sensitivity. The present structure should provide opportunities to design potent and selective PfSAHH inhibitors. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1007 / 1017
页数:11
相关论文
共 25 条
[1]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[2]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[3]  
BUIJUNICKI JM, 2003, PROTEIN-STRUCT FUNCT, V52, P624
[4]   BIOLOGICAL METHYLATION - SELECTED ASPECTS [J].
CANTONI, GL .
ANNUAL REVIEW OF BIOCHEMISTRY, 1975, 44 :435-451
[5]   Biological effects of inhibitors of S-adenosylhomocysteine hydrolase [J].
Chiang, PK .
PHARMACOLOGY & THERAPEUTICS, 1998, 77 (02) :115-134
[6]  
CREEDON KA, 1994, J BIOL CHEM, V269, P16364
[7]   Crystal structure of S-adenosylhomocysteine hydrolase from rat liver [J].
Hu, YB ;
Komoto, J ;
Huang, Y ;
Gomi, T ;
Ogawa, H ;
Takata, Y ;
Fujioka, M ;
Takusagawa, F .
BIOCHEMISTRY, 1999, 38 (26) :8323-8333
[8]   Inhibition of S-adenosylhomocysteine hydrolase by acyclic sugar adenosine analogue D-eritadenine -: Crystal structure of S-adenosylhomocysteine hydrolase complexed with D-eritadenine [J].
Huang, YF ;
Komoto, J ;
Takata, Y ;
Powell, DR ;
Gomi, T ;
Ogawa, H ;
Fujioka, M ;
Takusagawa, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (09) :7477-7482
[9]   MATRAS: a program for protein 3D structure comparison [J].
Kawabata, T .
NUCLEIC ACIDS RESEARCH, 2003, 31 (13) :3367-3369
[10]   Synthesis of 2-fluoronoraristeromycin and its inhibitory activity against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase [J].
Kitade, Y ;
Kojima, H ;
Zulfiqur, F ;
Kim, HS ;
Wataya, Y .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (22) :3963-3965